ĐẶC ĐIỂM LÂM SÀNG VÀ PHÂN TỬ CỦA BỆNH NHÂN UNG THƯ PHỔI KHÔNG TẾ BÀO NHỎ GIAI ĐOẠN IV CÓ ĐỘT BIẾN GEN KRAS

Abstract

Objectives: To describe the clinical and molecular characteristics of patients with stage IV non-small cell lung cancer (NSCLC) harboring KRAS mutations at K Hospital. Patients and method: A cross-sectional descriptive study was conducted on 147 patients with stage IV NSCLC confirmed to carry KRAS mutations by next-generation sequencing (NGS) at K Hospital, from January 2020 to December 2024. Results: The mean age was 61.8 years; 91.2% were male, and 82.3% had a history of smoking. Adenocarcinoma was predominant (93.2%), with most KRAS mutations located at codon 12, notably G12C (42.2%). Approximately 12.3% of patients harbored co-mutations, commonly STK11. Frequent metastatic sites included the contralateral lung, bone, pleura, and brain. Data on PD-L1 expression were limited. Conclusion: Stage IV NSCLC patients with KRAS mutations at K Hospital exhibited consistent clinical and molecular features, contributing to real-world data that may support prognosis and guide future personalized treatment approaches.